Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-month open-label phase 2 long-term extension of vamorolone in boys with Duchenne muscular dystrophy
MOH_2017-11-07_000767Phase 2Not yet recruiting
- Sponsor
- ReveraGen BioPharma
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vamorolone in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by ReveraGen BioPharma. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2017-11-07_000767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-07_000767.